EMILY ICHIKAWA: Open Payments
NPI 1255988234 · PALO ALTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$252 in 15 payments from 9 companies in 2025. Trend: 2023 $1,568 · 2024 $1,895 · 2025 $252
Food & beverage: $252
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $50 |
| PFIZER INC. | 3 | $47 |
| Astellas Pharma US Inc | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| ABBVIE INC. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Novo Nordisk Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Amgen Inc. | 1 | $14 |
Products named: NURTEC ODT, Veozah, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, ZENPEP, Ozempic, KISUNLA.
Industry payments across CA — which companies pay providers there.
